CION Ameerpet
Not every brain tumour needs chemo, and the right medicine depends on the tumour type and a molecular test. At CION, our medical oncologists deliver systemic therapy directly, guided by a tumour board for every patient.
Chemotherapy means medicines that travel through the body to kill or slow cancer cells. For brain tumours, it is one tool among several — used only for certain tumour types, and almost always alongside surgery and radiation rather than on its own. The honest starting point is this: many brain tumours are not treated with chemotherapy at all.
Benign tumours such as most meningiomas, and several slow-growing low-grade tumours, are managed with surgery, focused radiation, or careful monitoring. Chemotherapy comes into the plan mainly for malignant (cancerous) tumours — high-grade gliomas including glioblastoma, some grade 3 tumours, and brain metastases — and even then, whether it helps depends on the exact tumour and its molecular markers. This page explains, in plain language, when chemo is used, how it is given, what to expect, and how CION delivers it directly while coordinating the rest of your care.
For glioblastoma, NCCN and EANO (the European Association of Neuro-Oncology) guidelines recommend an alkylating chemotherapy given together with radiation after surgery, then continued in monthly cycles. The landmark trial behind this approach showed that adding chemotherapy to radiation improved survival compared with radiation alone — which is why it is now the international standard for newly diagnosed glioblastoma.
Chemotherapy is matched to the tumour type, not given to everyone. Here is where it genuinely changes the plan — and where it usually does not. The final call is always made by CION's neuro-oncology tumour board.
This is where chemotherapy matters most. After surgery, an alkylating chemotherapy is given alongside radiation, then continued in monthly cycles. A molecular test (MGMT) helps predict how well it is likely to work, which is why CION checks it on every malignant glioma sample before deciding the regimen.
Certain grade 3 gliomas — particularly those carrying IDH mutation and 1p/19q changes — respond well to a chemotherapy approach combined with radiation. Molecular testing identifies these tumours, so the medicine is chosen for the biology rather than the grade alone.
When cancer spreads to the brain from elsewhere, focused radiation is usually first. Systemic therapy — chemotherapy, targeted, or immunotherapy chosen for the original cancer — is layered in when it reaches and controls disease in the brain. See brain metastases treatment.
Most benign tumours (such as meningiomas), many low-grade tumours, and tumours fully removed by surgery often need no chemotherapy. For these, surgery, radiation therapy, or monitoring is the right path — and adding chemo would bring side effects without benefit.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
Talk to a CION medical oncologist about whether chemotherapy fits your tumour, how it would be given, and what to expect. We walk this journey with you, every step.
One of the challenges with brain tumours is the blood–brain barrier — a natural filter that protects the brain and also blocks many medicines from reaching it. This is the main reason only certain drug classes are useful, and why the route and schedule are chosen carefully. There are three main ways chemotherapy is delivered:
The most common approach for high-grade gliomas uses an alkylating chemotherapy taken as a capsule at home — usually daily during radiation, then on a monthly cycle (a few days on, then a rest period) afterwards. It is convenient, does not need a hospital stay, and is generally well tolerated, with blood counts checked before each cycle.
Some regimens — particularly certain combinations for grade 3 gliomas or for brain metastases — are given by drip in a day-care unit. Sessions are scheduled in cycles with rest periods so the body can recover between treatments. CION delivers these infusions directly at our centres with full monitoring and supportive care.
In a small number of selected cases, thin dissolvable chemotherapy wafers are placed in the cavity left after the tumour is removed, releasing medicine locally. This is decided at the time of surgery and is coordinated with our accredited neurosurgical partners — chemotherapy planning and follow-up are managed by CION's medical oncology team.
For glioblastoma and many high-grade gliomas, chemotherapy is not given alone. It is delivered at the same time as radiation — an approach the field calls chemoradiation — because the two together are more effective than radiation by itself. After radiation finishes, the chemotherapy continues in monthly cycles. This sequence is the internationally accepted standard set out in NCCN and EANO guidelines, and it is coordinated step-by-step with our radiation oncology team.
What makes modern brain-tumour chemotherapy different is that a test on the tumour tissue predicts whether the medicine is likely to work:
This is why CION arranges molecular testing on the biopsy of every malignant glioma — so chemotherapy is chosen on real evidence about your tumour, not on the grade alone. Ask CION whether your tumour has been tested before any chemo plan is finalised.
Most patients tolerate brain-tumour chemotherapy better than they fear. With the common oral alkylating medicine, the usual effects are tiredness, mild nausea, and a temporary dip in blood counts — and CION's team manages each of these proactively so you can keep up daily life.
After treatment, regular MRI scans track the tumour's response. The first scan after chemoradiation can be tricky to read — temporary inflammation can mimic tumour growth — so experienced neuro-oncologists avoid premature changes to a working plan.
Chemotherapy is just one part of brain tumour care — and almost never the whole plan. The most reliable outcomes come from a multidisciplinary tumour board where surgery, radiation, and medical oncology decide together, as recommended by NCCN and EANO. At CION, every brain tumour case is reviewed by the board before chemotherapy is started, stopped, or changed.
Chemotherapy decisions for a brain tumour are high-stakes, and a second opinion is especially valuable in a few situations:
CION offers a dedicated free written second opinion. To understand how chemotherapy sits within the complete pathway — surgery coordination, radiation, and supportive care — see our brain tumour treatment in Hyderabad page, explore targeted & immunotherapy options, or return to the brain cancer & tumour hub. You can also call us on 18002028726 to speak with the team.
Get a free written second opinion from CION's tumour board — particularly valuable if chemotherapy has been suggested without molecular testing (MGMT, IDH) on the tumour.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.No. Many brain tumours are not treated with chemotherapy at all. Benign tumours such as most meningiomas, and some slow-growing low-grade tumours, are managed with surgery, radiation, or careful monitoring. Chemotherapy is mainly used for certain malignant (cancerous) tumours — high-grade gliomas like glioblastoma, some grade 3 tumours, and brain metastases from other cancers. Whether chemo helps depends heavily on the exact tumour type and its molecular markers (such as MGMT and IDH). At CION, a multidisciplinary tumour board reviews every case before deciding if chemotherapy belongs in your plan.
It depends on the drug class. The most common medicine for high-grade gliomas is an alkylating chemotherapy taken as a tablet at home — usually daily during radiation, then in monthly cycles afterwards. Some other regimens are given by drip (infusion) in a day-care unit. A small number of patients receive wafers placed in the cavity during surgery that release chemo locally. Your medical oncologist chooses the route and schedule based on tumour type, your general health, and how the drug crosses into the brain. CION delivers systemic (medical) therapy directly at our centres.
For glioblastoma and many high-grade gliomas, an alkylating chemotherapy is given at the same time as radiation — a combined approach the field calls chemoradiation. The two together are more effective than radiation alone, and chemotherapy then continues in monthly cycles after radiation ends. This sequence is the internationally accepted standard described in NCCN and EANO guidelines. You can read how it fits the wider plan on our radiation therapy for brain tumours and brain tumour treatment pages. The decision is always made by the tumour board.
For glioblastoma, a test on the tumour sample called MGMT methylation predicts how well alkylating chemotherapy is likely to work — patients whose tumour has a methylated MGMT gene tend to benefit more. The IDH mutation and 1p/19q status also guide which chemotherapy approach suits a glioma and how it is likely to behave over time. This is why CION arranges molecular testing on the biopsy of every malignant glioma — so chemotherapy is chosen on evidence, not guesswork. Learn more on our molecular testing for brain tumours page.
Most patients tolerate brain-tumour chemotherapy better than they expect. With the common oral alkylating drug, the usual effects are tiredness, mild nausea (well controlled with anti-sickness medicine), and a temporary drop in blood counts — which is why regular blood tests are done. Hair loss is uncommon with the standard oral regimen. Infusion regimens have their own profiles. Your CION team monitors counts, adjusts doses if needed, and manages symptoms so you can keep up daily activities. Steroids and seizure medicines are coordinated alongside, as many brain tumour patients need them.
Sometimes — but it is usually not the first tool. Brain metastases (cancer that has spread to the brain from elsewhere) are most often treated with focused radiation such as stereotactic radiosurgery. Systemic therapy — chemotherapy, targeted therapy, or immunotherapy chosen for the original cancer — is layered in when the medicines reach the brain and control disease there. The right combination depends on where the cancer started, so we cross-link the primary cancer plan (for example lung or breast cancer). CION coordinates this for you.
Browse our complete guide to brain tumours and brain cancer — symptoms, scans, tumour types, treatment, prognosis and life after treatment. Tap any topic to read more.